By Colin Kellaher 



  Germany's CureVac B.V., which is working on a coronavirus vaccine, on Monday said it plans to sell about 13.3 million shares at between $14 and $16 each in its planned U.S. initial public offering. 


  At the $15 midpoint of that range, the Tubingen, Germany, company said it expects net proceeds of about $182.7 million, or roughly $210.6 million if the underwriters exercise an option to buy an additional 2 million shares. 


  CureVac said Dietmar Hopp, managing director of majority shareholder Dievini Hopp BioTech Holding GmbH, has agreed to buy 100 million euros (US$118 million) of common stock at the IPO price in a concurrent private placement. 


  CureVac said it will spend about $150 million to fund clinical development of its vaccine program against SARS-CoV-2, the virus that causes Covid-19, through the completion of a phase 3 clinical trial. 


  CureVac's backers also include German state-owned bank KfW, which holds an 18.3% stake, and GlaxoSmithKline PLC, which in July said it would invest about $170 million for a nearly 10% stake in the biotechnology company. 


  CureVac said it has applied to list its shares on the Nasdaq Global Market under the symbol CVAC. 


  Write to Colin Kellaher at colin.kellaher@wsj.com